Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Avaxia Biologics, Incorporated
ClinicalTrials.gov Identifier:
NCT01759056
First received: December 24, 2012
Last updated: March 4, 2014
Last verified: February 2014
  Purpose

The purpose of this study is to evaluate the safety and tolerability as well as the pharmacodynamic effects of multiple doses of AVX-470 administered orally in patients with active ulcerative colitis.


Condition Intervention Phase
Ulcerative Colitis
Drug: AVX 470
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis

Resource links provided by NLM:


Further study details as provided by Avaxia Biologics, Incorporated:

Primary Outcome Measures:
  • Safety and tolerability of AVX-470 over 28 days of treatment [ Time Frame: 5 weeks ] [ Designated as safety issue: Yes ]
    Assessments weekly during treatment and 1 week post treatment


Secondary Outcome Measures:
  • Pharmacokinetics (serum, stool and gastrointestinal mucosal tissue levels) of AVX-470 [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
  • Measure the induction of or change in a human anti-bovine immunoglobulin antibody (HABA) response to AVX 470 [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]

Other Outcome Measures:
  • Clinical response to AVX 470 in ulcerative colitis, as assessed by the total Mayo score and subscores, after 28 days of treatment compared to Baseline [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
  • Effect of AVX 470 on endoscopic healing in ulcerative colitis, as assessed by the endoscopic subscore of the total Mayo score and the Ulcerative Colitis Index of Severity (UCEIS), after 28 days of treatment compared to Baseline [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
  • Evaluate the effects of AVX 470 on biomarkers of ulcerative colitis activity over 28 days of treatment compared to Baseline [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 33
Study Start Date: February 2013
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: AVX 470
AVX 470 0.2 g(Cohort 1), 1.6 g (Cohort 2) and 3.5 g (Cohort 3) will be administered daily for 28 days
Drug: AVX 470
active comparator
Placebo Comparator: Placebo
Placebo will be administered daily for 28 days as a comparator with AVX-470 (all dose groups)
Drug: Placebo

Detailed Description:

There is a significant unmet medical need for effective oral pharmacologic therapies for inflammatory bowel diseases such as ulcerative colitis. Current anti-TNF therapies, including infliximab and adalimumab, are effective treatments for these conditions, but they must be administered by intravenous or subcutaneous injection. The major safety concerns associated with the use of injectable anti-TNF therapies are infection, demyelinating disease, and lymphoma, all of which are the result of systemic exposure. These uncommon but serious side effects have limited the use of systemic anti-TNF antibody therapy to patients with severe disease that have failed to respond to first-line treatments.

AVX-470 is purified immunoglobulin (Ig) from the colostrum (early milk) of cows immunized with recombinant human tumor necrosis factor (rhTNF). AVX-470 is formulated in delayed-release enteric-coated capsules designed to protect the capsule contents from gastric acids following oral administration and to provide localized delivery to sites of inflammation in the distal intestine. Prior clinical experience with bovine Ig therapies in other human diseases suggests that AVX-470 will not be absorbed to any significant extent, meaning that systemic exposure could be minimized. The development of oral anti-TNF therapy targeting local intestinal disease activity might reduce the risks associated with injectable anti-TNF therapy and allow the convenience of oral dosing.

The present study is a first-in-human, Phase 1 clinical study. It is primarily intended to evaluate the safety and tolerability of multiple doses of AVX-470 administered orally to patients with active ulcerative colitis.

Animal models of ulcerative colitis using a mouse-specific TNF antibody derived from bovine colostrum demonstrated a 50% or more reduction in tissue TNF, TNF-messenger ribonucleic acid (mRNA), interleukin (IL)-6 mRNA, and myeloperoxidase and lowering of colonic inflammatory activity. Twenty-eight-day toxicology studies demonstrated no clinical or histologic findings in exposures above the intended clinical dose range.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women aged 18 75, inclusive
  • Established diagnosis of ulcerative colitis involving the sigmoid colon or proximal segments of bowel
  • Total Mayo score between 5-12, inclusive, with endoscopic subscore of the Mayo score ≥ 2 and > 15 cm of involvement beyond the anal verge

Exclusion Criteria:

  • Women with a positive pregnancy test, who are breastfeeding, or who intend to become pregnant during the course of the study
  • Diagnosis of Crohn's disease, microscopic colitis or indeterminate colitis
  • Presence of ileostomy or colostomy, or history of prior colon resection
  • Patients with planned hospitalization or surgery during the course of the study
  • Known allergy to milk proteins, red meat or cornstarch
  • Stools positive for enteric infection, including parasitic, or C. difficile toxin within 28 days of screening
  • Documented presence of Hetatitis B (HBsAg), Hepatitis C (HCV), or HIV
  • Presence of dysplasia of any grade on colonoscopic biopsies
  • Treatment for cancer (excluding non-melanomatous cancer of the skin or cervical carcinoma in situ) or lymphoproliferative disorder (including lymphoma) within 5 years
  • History of tuberculosis (TB) or Listeria infection, or known exposure to another person with active TB disease within 12 weeks of screening; or history of past or current infection with different opportunistic infections
  • History of TNF inhibitor (infliximab, adalimumab or certolizumab pegol) use with primary treatment failure. Secondary treatment failures due to intolerance, allergic reaction, or loss of response will not constitute a basis for exclusion. Oral immunosuppressives, mesalamine, and corticosteroids (up to 20mg of prednisone per day) will be permitted so long as these medications are stable for defined periods of time before study participation commences.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01759056

Locations
United States, California
Anaheim Clinical Trials
Anaheim, California, United States, 92801
United States, Colorado
Rocky Mountain Gastroenterology Associates
Lakewood, Colorado, United States, 80215
United States, Florida
Shafran Gastroenterology Center
Winter Park, Florida, United States, 327789
United States, Maryland
Chevy Chase Clinical Research
Chevy Chase, Maryland, United States, 20815
United States, Michigan
Clinical Research Institute of Michigan
Chesterfield, Michigan, United States, 48047
United States, Missouri
Center for Digestive and Liver Disease
Mexico, Missouri, United States, 65265
United States, Ohio
Remington-Davis, Inc.
Columbus, Ohio, United States, 43215
United States, Oklahoma
Oklahoma Foundation for Digestive Research
Oklahoma City, Oklahoma, United States, 73104
United States, Tennessee
Nashville Medical Research Institute
Nashville, Tennessee, United States, 37205
Belgium
Gastro-Enterologie
Gent, Belgium, 9000
Gastro-enterologie
Leuven, Belgium, 3000
Canada, Alberta
The Northern Alberta Clinical Trials and Research Centre
Edmonton, Alberta, Canada, T6G 2C8
Canada, Ontario
Toronto Digestive Disease Associates
Toronto, Ontario, Canada, L4L 4Y7
Hungary
Semmelweis Egyetem
Budapest, Hungary, 1083
Kenézy Kórház Rendelöintézet Egészségügyi Szolgáltató Kft.
Debrecen, Hungary, 4043
Debreceni Egyetem Orvos- és Egészségtudományi Centrum
Debrecen, Hungary, 4032
Sponsors and Collaborators
Avaxia Biologics, Incorporated
Investigators
Study Director: Scott Harris, MD Avaxia Biologics, Incorporated
  More Information

No publications provided

Responsible Party: Avaxia Biologics, Incorporated
ClinicalTrials.gov Identifier: NCT01759056     History of Changes
Other Study ID Numbers: AB1101, 2012-004850-27
Study First Received: December 24, 2012
Last Updated: March 4, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Avaxia Biologics, Incorporated:
Ulcerative colitis

Additional relevant MeSH terms:
Colitis
Colitis, Ulcerative
Ulcer
Colonic Diseases
Digestive System Diseases
Gastroenteritis
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on October 20, 2014